A 68-year-old woman with Parkinson disease of 8 years' duration, currently on levodopa 750 mg/day with carbidopa, presents with involuntary writhing movements of her limbs and trunk that occur 2–3 hours after each dose of medication. She also reports periods of sudden immobility ('off' episodes) lasting 15–20 minutes between doses. Her Montreal Cognitive Assessment is 26/30. What is the most appropriate next step in her management?

Explanation

## Clinical Syndrome Recognition This patient exhibits **motor complications** of long-term levodopa therapy: | Feature | Interpretation | |---------|----------------| | Involuntary writhing movements (dyskinesias) | **Peak-dose dyskinesia** — occurs when levodopa levels are highest | | Sudden immobility ('off' episodes) | **Motor fluctuations** — loss of effect between doses | | Timing: 2–3 hrs post-dose | Classic pattern of levodopa-induced dyskinesia | | Disease duration: 8 years | Long-term levodopa exposure increases complication risk | ## Pathophysiology of Motor Complications **Key Point:** After 5–10 years of levodopa therapy, pulsatile dopaminergic stimulation (due to short half-life of levodopa ~90 min) causes: 1. Sensitization of postsynaptic dopamine receptors 2. Abnormal gene expression in striatal neurons 3. Loss of buffering capacity in denervated striatum 4. Result: dyskinesias and motor fluctuations ## Management Strategy for Motor Complications ```mermaid flowchart TD A[Motor complications on levodopa]:::outcome --> B{Cognitive status?}:::decision B -->|Intact| C[Optimize levodopa dosing]:::action C --> D[Add COMT inhibitor<br/>entacapone/tolcapone]:::action D --> E[Add dopamine agonist<br/>or MAO-B inhibitor]:::action E --> F{Adequate control?}:::decision F -->|Yes| G[Continue combination]:::outcome F -->|No| H[Consider DBS]:::action B -->|Impaired| I[Simplify regimen<br/>Avoid polypharmacy]:::action I --> J[Consider DBS if severe]:::action ``` ## Why Entacapone + Agonist Augmentation? **High-Yield:** The stepwise approach to motor complications: 1. **Optimize levodopa timing** — reduce interval between doses (not increase total dose, which worsens dyskinesias) 2. **Add COMT inhibitor** (entacapone) — prolongs levodopa half-life by ~30%, smooths dopaminergic levels, reduces fluctuations 3. **Add dopamine agonist** — provides additional dopaminergic tone, reduces levodopa requirement, improves 'off' episodes 4. **DBS** — reserved for patients with inadequate medical control or intolerable side effects **Clinical Pearl:** This patient has: - Intact cognition (MoCA 26/30) → can tolerate polypharmacy - 8 years disease duration → established motor complications - Dyskinesias + fluctuations → needs dual intervention (COMT inhibitor + agonist) **Warning:** Simply increasing levodopa dose will worsen dyskinesias; the problem is not insufficient dopamine but pulsatile delivery. ## Why NOT the Other Options? - **Increasing levodopa alone** → worsens dyskinesias (pulsatile effect) - **Switching to agonist monotherapy** → inadequate efficacy after 8 years; patient needs levodopa - **DBS immediately** → premature; medical optimization not yet exhausted; DBS reserved for refractory cases [cite:Harrison 21e Ch 451; Movement Disorders Society Guidelines 2023]